Recombinant Mouse Sphingosine 1-phosphate receptor 1 (S1pr1)

What is mouse S1PR1 and how does it function in cellular systems?

S1PR1 is a G protein-coupled receptor that primarily couples to Gi proteins. This receptor recognizes sphingosine-1-phosphate (S1P), a bioactive sphingolipid metabolite generated through the phosphorylation of sphingosine by sphingosine kinases (SPHK1 and SPHK2). S1PR1 regulates diverse cellular processes including cell growth, survival, differentiation, migration, and plays crucial roles in lymphocyte trafficking, vascular integrity, and inflammatory responses .

Unlike other S1P receptors, S1PR1 couples exclusively to Gi proteins, making it unique in the S1PR family. This exclusive coupling pattern explains why S1PR1 activation typically leads to inhibition of adenylyl cyclase, resulting in decreased cAMP production .

How does S1PR1 expression vary across mouse tissues and cell types?

S1PR1 shows differential expression across various tissues and cell types. Analysis of single-cell RNA sequencing data has revealed that S1PR1 mRNA is most abundant in hepatocytes compared to other cell types such as bone marrow monocytes and macrophages . In immune cells, S1PR1 is widely expressed across various types, including T cells, B cells, and macrophages .

Under pathological conditions such as non-alcoholic steatohepatitis (NASH), S1PR1 expression in bone marrow-derived macrophages (BMDMs) increases in response to lipotoxic stress induced by palmitate treatment, while expression in primary mouse hepatocytes remains unchanged . In whole liver tissue from mice fed a fast food diet (FFC), S1PR1 expression shows no significant change compared to control diet-fed animals .

What are the primary signaling pathways activated by S1PR1 in mice?

S1PR1 primarily activates Gi protein-mediated signaling pathways that lead to:

• Inhibition of adenylyl cyclase, resulting in decreased cAMP production

• Activation of phosphoinositide 3-kinase (PI3K) and subsequent Akt signaling

• Stimulation of Rac GTPase, promoting cell migration

• Activation of extracellular signal-regulated kinases (ERK)

These pathways collectively regulate cell survival, proliferation, migration, and cytoskeletal rearrangements . Recent studies have demonstrated that specific Gi-biased agonists like SAR247799 can selectively activate S1PR1-Gi signaling, which protects endothelial barrier integrity without affecting immune cell egress .

What are the most reliable methods to assess S1PR1 expression in mouse tissue samples?

Several complementary approaches can be used to accurately assess S1PR1 expression:

• qRT-PCR: For mRNA expression analysis, quantitative PCR remains a reliable method. When analyzing S1PR1-5 expression in different tissues, ensure proper primer design and validation for specificity across the closely related receptor subtypes .

• Immunohistochemistry/Immunofluorescence: For protein localization and expression. Recent studies have employed this technique to detect S1PR1 in tissue sections. Important controls include receptor knockout tissues or cells to validate antibody specificity .

• Western blotting: For total protein expression. Key considerations include proper membrane preparation techniques since S1PR1 is a membrane protein.

• Radioligand binding assays: [³H]CS1P1 has been used in autoradiograph studies to visualize S1PR1 expression patterns with high specificity and sensitivity .

• Single-cell RNA sequencing: For cell-type specific expression analysis across heterogeneous tissues. This approach has revealed valuable insights into differential expression patterns of S1PR1 across various cell types .

How can researchers effectively manipulate S1PR1 expression or activity in mouse models?

Several approaches can be employed to modulate S1PR1 expression or activity:

• Pharmacological modulators:

  • FTY720 (Fingolimod): Functional antagonist of S1PR1, 3, 4, and 5

  • Etrasimod: Selective antagonist of S1PR1, partial antagonist of S1PR4 and S1PR5

  • Amiselimod: Selective S1PR1 antagonist

  • SAR247799: Gi-biased agonist of S1PR1

• Genetic approaches:

  • Conditional knockout models using Cre-loxP system for tissue-specific deletion

  • Inducible knockout systems (e.g., tamoxifen-inducible) for temporal control

  • CRISPR/Cas9-mediated genome editing for precise receptor modifications

• Adenoviral or AAV-mediated gene delivery: Effective for acute manipulation of S1PR1 expression in specific tissues, as demonstrated in heart failure models where increasing S1PR1 density through gene therapy showed therapeutic potential .

• Antisense oligonucleotides or siRNA approaches: For transient knockdown of S1PR1 expression.

When using pharmacological modulators, researchers should consider the selectivity profile of each compound against different S1PR subtypes to accurately interpret experimental outcomes .

What methods are optimal for investigating S1PR1-protein interactions?

To investigate protein-protein interactions involving S1PR1:

• Co-immunoprecipitation: Effective for detecting native protein interactions, as demonstrated in studies investigating β1-adrenergic receptor and S1PR1 interactions .

• Proximity ligation assay (PLA): Enables visualization of protein interactions in situ with high sensitivity.

• FRET/BRET assays: For real-time monitoring of protein interactions in living cells.

• Cryo-electron microscopy: Recently employed to determine the structure of the S1PR1-Gi signaling complex bound to the biased agonist SAR247799 at 3.47Å resolution, revealing the recognition mode for this biased ligand .

• Cross-linking mass spectrometry: For identifying interaction interfaces between S1PR1 and partner proteins.

For all these methods, appropriate controls are essential, including the use of receptor mutants that disrupt potential interaction sites and competition with specific ligands that may enhance or disrupt the interactions .

How does S1PR1 modulation affect inflammatory processes in mouse models?

S1PR1 modulation has profound effects on inflammatory processes through several mechanisms:

• Lymphocyte trafficking regulation: S1PR1 antagonists prevent lymphocyte egress from lymphoid organs, reducing immune cell infiltration into inflamed tissues .

• Macrophage accumulation: Studies in NASH models show that S1PR1 antagonists (Etrasimod, Amiselimod) reduce inflammatory macrophage accumulation in the liver .

• Inflammatory cell infiltration: Etrasimod reduces liver inflammatory infiltrates including T cells, B cells, and NKT cells in dietary models of murine NASH .

• Endothelial barrier function: Gi-biased S1PR1 agonists like SAR247799 protect the integrity of the endothelial barrier without affecting immune cell egress, offering a novel approach to treating endothelial dysfunction-associated inflammatory diseases like IBD .

Experimental data from NASH models demonstrate that selective inhibition of S1PR receptors reverses adverse features of NASH, establishing a mechanistic link between S1P/S1PR signaling and immune inflammatory responses .

What role does S1PR1 play in cardiovascular pathophysiology?

S1PR1 has several important functions in cardiovascular pathophysiology:

• Interaction with β1-adrenergic receptor (β1AR): Studies have identified a direct and GRK2-dependent interaction between β1AR and S1PR1 in cardiomyocytes. These receptors exhibit reciprocal downregulation, which significantly impacts cardiac hypertrophy, apoptosis, and remodeling .

• Cardioprotective effects: S1PR1 signaling demonstrates cardioprotective properties, particularly during sustained catecholamine stimulation that mimics pathological conditions such as heart failure .

• Counterbalancing β1AR overstimulation: Restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious effects of β1AR overstimulation in heart failure .

• Regulation of apoptosis: While β1AR can induce significant apoptosis in cardiomyocytes, S1PR1 does not. More importantly, the apoptotic response to isoproterenol stimulation increases when the S1PR1 receptor is blocked, further supporting the cardioprotective role of S1PR1 .

In rat models of post-ischemic heart failure, S1PR1 plasma membrane levels are significantly downregulated, suggesting that S1PR1 inactivation might contribute to heart failure progression .

What are the emerging therapeutic applications targeting S1PR1 in mouse disease models?

Several promising therapeutic applications targeting S1PR1 have emerged from mouse disease models:

• Non-alcoholic steatohepatitis (NASH): Both Etrasimod (S1PR1,4,5 modulator) and Amiselimod (selective S1PR1 modulator) attenuate liver injury in dietary NASH models, with Etrasimod showing greater efficacy in reducing inflammatory cell infiltration .

• Inflammatory bowel disease (IBD): Gi-biased S1PR1 agonist SAR247799 reverses pathology in mouse and organoid IBD models by protecting endothelial barrier integrity without affecting immune cell egress, potentially offering advantages over current S1PR1 modulators that increase the risk of immunosuppression .

• Heart failure: Gene therapy to increase S1PR1 density in failing cardiomyocytes represents a novel therapeutic strategy, as S1PR1 counteracts the deleterious effects of β1AR overstimulation .

• Multiple sclerosis: The development of radiotracers like [¹¹C]CS1P1 for S1PR1 enables evaluation of therapeutic response to S1PR1-targeting drugs in MS models .

These applications highlight the versatility of S1PR1 as a therapeutic target across multiple disease contexts, with emerging strategies focused on selective modulation of specific signaling pathways or receptor-receptor interactions .

How do receptor-specific S1PR1 modulators differ from pan-S1PR modulators in their effects?

Comparison of receptor-specific and pan-S1PR modulators reveals important differences in efficacy and side effect profiles:

The relative efficacy of Etrasimod compared to Amiselimod in NASH models suggests that modulation of multiple S1P receptors (S1PR1, 4, and 5) may provide additional therapeutic benefits compared to selective S1PR1 modulation alone. This may be particularly relevant in macrophage-mediated inflammation, as S1PR4 mRNA is most abundant in macrophages and monocytes .

What are the molecular mechanisms underlying S1PR1 and β1-adrenergic receptor cross-talk?

The interaction between S1PR1 and β1AR represents a complex cross-talk mechanism with significant physiological implications:

• Reciprocal regulation: In HEK293 cells overexpressing both receptors, β1AR downregulation occurs after stimulation with sphingosine-1-phosphate (S1PR1 agonist), while S1PR1 downregulation is triggered by isoproterenol (β-adrenergic receptor agonist) .

• GRK2 dependence: This cross-talk is mediated by G-protein–coupled receptor kinase-2 (GRK2), which triggers desensitization and downregulation processes for both receptors .

• Opposing G-protein coupling: S1PR1 and β1AR couple to different G-proteins (Gi and Gs, respectively), resulting in opposing actions on adenylyl cyclase activity and cAMP production .

• Physiological significance: This interaction has been demonstrated in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in rat models of post-ischemic heart failure, suggesting its relevance in cardiac pathophysiology .

• Therapeutic implications: The cardioprotective effects of S1PR1 can counterbalance the deleterious effects of β1AR overstimulation, suggesting that increasing S1PR1 expression could be therapeutic in heart failure .

This cross-talk mechanism expands our understanding beyond classic signaling paradigms, where simultaneous activation of these receptors would simply result in opposing actions on cAMP production .

How can structural insights inform the development of biased S1PR1 ligands?

Recent structural biology advances have provided valuable insights for developing biased S1PR1 ligands:

• Cryo-electron microscopy structure: The structure of the S1PR1-Gi signaling complex bound to the Gi-biased agonist SAR247799 at 3.47Å resolution has revealed the specific recognition mode for this biased ligand .

• Structure-function relationships: Understanding the structural basis of biased signaling enables rational design of ligands that selectively activate beneficial pathways while avoiding unwanted effects.

• Therapeutic applications: Gi-biased S1PR1 agonists like SAR247799 can protect endothelial barrier integrity without affecting immune cell egress, potentially addressing a major limitation of current S1PR1 modulators that increase immunosuppression risk .

• Target engagement evaluation: Structural insights also facilitate the development of imaging probes like [¹¹C]CS1P1 for evaluating target engagement and therapeutic response in vivo .

These structural studies represent a significant advance in our understanding of S1PR1 signaling and provide a foundation for developing next-generation therapeutics with improved efficacy and safety profiles .

What are emerging areas for S1PR1 research in mouse models?

Several promising research directions are emerging in the field:

• Cell type-specific S1PR1 functions: Investigating how S1PR1 signaling differs between endothelial cells, immune cells, and other cell types to develop more targeted therapeutic approaches .

• Biased signaling: Further exploration of biased S1PR1 agonists that selectively activate specific downstream pathways, building on recent success with Gi-biased agonists for endothelial barrier protection .

• Receptor-receptor interactions: Expanding on discoveries of S1PR1 cross-talk with other receptors beyond β1AR, potentially uncovering new regulatory mechanisms and therapeutic targets .

• S1PR1 in metabolic diseases: While S1PR1 modulators show promise in NASH models, their potential in other metabolic disorders remains to be fully explored .

• Imaging and biomarker development: Advancing tools like [¹¹C]CS1P1 for in vivo imaging to better understand S1PR1 expression and function in various disease states .

What methodological challenges remain in studying S1PR1 in complex disease models?

Despite significant advances, several challenges persist in S1PR1 research:

• Receptor redundancy: The presence of five S1P receptor subtypes with overlapping functions complicates the interpretation of phenotypes in genetic and pharmacological studies.

• Cell type-specific effects: S1PR1 signaling can have different or even opposing effects in different cell types, necessitating the development of cell type-specific targeting approaches .

• Dynamic regulation: S1PR1 undergoes complex regulatory processes including internalization, recycling, and degradation, which can be difficult to track in vivo.

• Cross-talk mechanisms: Interactions with other signaling pathways and receptors add layers of complexity that require sophisticated experimental designs to unravel .

• Translation to human disease: While mouse models provide valuable insights, translating findings to human diseases requires careful consideration of species differences in receptor expression, distribution, and signaling.

Addressing these challenges will require integrated approaches combining genetic, pharmacological, structural, and systems biology methods to fully elucidate S1PR1 biology in health and disease.